Sandostatin

Sandostatin Patient Counseling Information

octreotide

Manufacturer:

Novartis

Distributor:

DKSH
Full Prescribing Info
Patient Counseling Information
Recommendation for the management of patients during Sandostatin treatment with respect to the development of gallstones.
1. Patients should undergo a baseline ultrasound examination of the gallbladder prior to commencing octreotide treatment.
2. Periodic repeat ultrasound examination of the gallbladder should be performed, preferably at about 6-month intervals, throughout Sandostatin treatment.
3. If stones are already present before the start of therapy, the potential benefit of Sandostatin should be assessed against the potential risks associated with the gallstones. There is no evidence at present that Sandostatin adversely affects the course or prognosis of preexisting gallstones.
4. Management of patients who develop gallstones in association with Sandostatin: i. Asymptomatic gallstones: Sandostatin may be continued, depending on re-assessment of the benefit/risk ratio. Either way, no action is required except to continue monitoring, with increased frequency if this is considered necessary.
ii. Symptomatic gallstones: Sandostatin may be either stopped or continued, depending on re-assessment of the benefit/risk ratio. Either way, the gallstones should be treated like any other symptomatic gallstones. Medically, this may include combined bile acid therapy (e.g. chenodeoxycholic acid [CDCA] together with ursodeoxycholic acid [UDCA] or monotherapy with ursodeoxycholic acid (UDCA) associated with ultrasound monitoring until the stones have completely disappeared. For posology and treatment duration, consult the locally approved prescribing information for CDCA and/or UDCA.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in